This month, we are focusing on formulation services offered by XenoGesis and its selected CDMO partners.
To kick things off, we interviewed Rob Harris, Director of Beyond Quality, a pharmaceutical development consultancy. Rob is a pharmaceutical scientist with over 30 years’ experience in R&D, having held a number of technical roles including Quay Pharma, Juniper Pharma Services and most recently, Catalent Pharma Solutions. Rob’s expertise is in formulation development and manufacture of pharmaceutical dosage forms (including solid and liquid orals; immediate and controlled release, topicals, inhaled products, ophthalmics and parenterals). His particular specialism lies in the development of formulations for drugs with poor solubility/bioavailability, using a wide range of enabling technologies.
XenoGesis has a long-standing relationship with Rob, working together on numerous projects.
In this interview, we ask Rob about how the manufacture of small molecules has evolved over the years; the key considerations of the ‘developability’ of a molecule; the benefits of integrating DMPK and formulation development; as well as the common mistakes made and how these can be avoided.
The interview was recorded using Zoom in September 2020.
To find out more about how XenoGesis, along with our CDMO partners, can help you with your formulation development, get in touch and talk to one of our scientists.